Skip to content

Progesterone vaginal vs oral progesterone in the natural cycle of thawed embryo transfer luteal support: A multi-center prospective randomized clinical trial

Progesterone vaginal vs oral progesterone in the natural cycle of thawed embryo transfer luteal support: A multi-center prospective randomized clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-16009248
Enrollment
Unknown
Registered
2016-09-22
Start date
2016-10-10
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inferitility

Interventions

Dydrogesterone group:frozen-thawed embryo transfer,luteal phase support, follow up
Progesterone Soft Capsules group:frozen-thawed embryo transfer, luteal phase support,follow up

Sponsors

Yantai Yuhuangding Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 38 Years

Inclusion criteria

Inclusion criteria: 1. women who prepare for a frozen embryo transplant; 2. Women who have =1 years history of infertility; 3. Women aged 20 to 38 years old; 4. Women who have regular menstrual cycle 25-35 days and normal ovulation; 5. Hysteroscopy for uterine cavity lesions; 6. Women who are capable of giving informed consent.

Exclusion criteria

Exclusion criteria: 1. Women diagnosed as uterus abnormality: malformed uterus (uterus unicornis, septate uterus, duplex uterus, uterus bicomis), adenomyosis, submucous myoma, intrauterine adhesion; 2. Women or their partner with abnormal chromosome karyotype including chromosome polymorphism; 3. Women who have experienced recurrent spontaneous abortion (including biochemical pregnancy abortion) more than 2 times; 4. Women with medical condition that represent contraindication to assisted reproductive technology and/or pregnancy, such as poorly controlled Type I or Type II diabetes; undiagnosed liver disease or dysfunction (based on serum liver enzyme testing); renal disease or abnormal serum renal function; significant anemia; history of deep venous thrombosis, pulmonary embolus, or cerebrovascular accident; uncontrolled hypertension, known symptomatic heart disease; history of or suspected cervical carcinoma, endometrial carcinoma, or breast carcinoma; undiagnosed vaginal bleeding; 5. Women who are unable to comply with the study procedures.

Design outcomes

Primary

MeasureTime frame
clinical pregnancy rate;pregnancy loss rate;Vaginal bleeding rate;Ectopic pregnancy rate;Live birth rate;congenital anomalies rate;

Countries

China

Contacts

Public ContactCuifang Hao

Yantai Yuhuangding Hospital

cuifang-hao@163.com+86 0535-6691999-82503

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026